Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.15 CAD | +3.45% | -3.33% | +81.25% |
03-26 | Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 | CI |
03-25 | Marvel Biosciences Announces Positive Interim Results For MB-204 | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joseph Matheson
CEO | Chief Executive Officer | - | 21-06-13 |
Harry Nijjar
DFI | Director of Finance/CFO | 36 | 22-01-31 |
Mark Williams
PSD | President | 52 | 21-06-13 |
Jacqueline Groot
SEC | Corporate Secretary | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
S. Smallbone
BRD | Director/Board Member | - | 22-02-14 |
Joseph Matheson
CEO | Chief Executive Officer | - | 21-06-13 |
Mark Williams
PSD | President | 52 | 21-06-13 |
Director/Board Member | 55 | 21-06-13 | |
Babak Pedram
BRD | Director/Board Member | 43 | 22-11-22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 39,786,231 | 27,910,633 ( 70.15 %) | 0 | 70.15 % |
Company contact information
Marvel Biosciences Corp.
505 8th Avenue South West Suite 420
T2P 1G2, Calgary
+
http://www.marvelbiotechnology.comSector
1st Jan change | Capi. | |
---|---|---|
+81.25% | 4.22M | |
+21.76% | 47.9B | |
+46.62% | 41.42B | |
-2.18% | 40.7B | |
-6.20% | 28.92B | |
+10.19% | 25.55B | |
-20.87% | 19.27B | |
-0.32% | 12.15B | |
+31.04% | 12.14B | |
-0.47% | 11.99B |
- Stock Market
- Equities
- MRVL Stock
- Company Marvel Biosciences Corp.